Literature DB >> 10577987

Anti-TNF antibody treatment of Crohn's disease.

S J van Deventer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10577987      PMCID： PMC1766571          DOI： 10.1136/ard.58.2008.i114

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  93 in total

1.  Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease.

Authors:  W A Stack; S D Mann; A J Roy; P Heath; M Sopwith; J Freeman; G Holmes; R Long; A Forbes; M A Kamm
Journal:  Lancet       Date:  1997-02-22       Impact factor: 79.321

Review 2.  Epidemiology of inflammatory bowel disease: an update.

Authors:  M G Russel; R W Stockbrügger
Journal:  Scand J Gastroenterol       Date:  1996-05       Impact factor: 2.423

Review 3.  Role of NF-kappaB in immune and inflammatory responses in the gut.

Authors:  M F Neurath; C Becker; K Barbulescu
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

4.  Advances in mucosal immunity.

Authors:  C O Elson
Journal:  Drugs       Date:  1997       Impact factor: 9.546

5.  Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study.

Authors:  R Löfberg; P Rutgeerts; H Malchow; C Lamers; A Danielsson; G Olaison; D Jewell; O Ostergaard Thomsen; H Lorenz-Meyer; H Goebell; H Hodgson; T Persson; C Seidegård
Journal:  Gut       Date:  1996-07       Impact factor: 23.059

6.  Crohn's disease after in-utero measles virus exposure.

Authors:  A Ekbom; P Daszak; W Kraaz; A J Wakefield
Journal:  Lancet       Date:  1996-08-24       Impact factor: 79.321

7.  Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis.

Authors:  M Boirivant; M Marini; G Di Felice; A M Pronio; C Montesani; R Tersigni; W Strober
Journal:  Gastroenterology       Date:  1999-03       Impact factor: 22.682

8.  CD4+ intestinal mucosal lymphocytes in the pathogenesis of Crohn's disease.

Authors:  M Watanabe; H Takaishi; Y Hosoda; T Ezaki; T Yajima; N Inoue; Y Ueno; Y Iwao; H Ishii; H Ishikawa
Journal:  J Gastroenterol       Date:  1995-11       Impact factor: 7.527

9.  A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

Authors:  O O Thomsen; A Cortot; D Jewell; J P Wright; T Winter; F T Veloso; M Vatn; T Persson; E Pettersson
Journal:  N Engl J Med       Date:  1998-08-06       Impact factor: 91.245

10.  Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells.

Authors:  H Groux; M Bigler; J E de Vries; M G Roncarolo
Journal:  J Exp Med       Date:  1996-07-01       Impact factor: 14.307
View more
  5 in total

Review 1.  From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease.

Authors:  Charles W Randall; John A Vizuete; Nicholas Martinez; John J Alvarez; Karthik V Garapati; Mazyar Malakouti; Carlo M Taboada
Journal:  Therap Adv Gastroenterol       Date:  2015-05       Impact factor: 4.409

Review 2.  Cytokine regulation of tight junctions.

Authors:  Christopher T Capaldo; Asma Nusrat
Journal:  Biochim Biophys Acta       Date:  2008-10-08

Review 3.  Tumour necrosis factor and cancer.

Authors:  Frances Balkwill
Journal:  Nat Rev Cancer       Date:  2009-04-03       Impact factor: 60.716

Review 4.  Oral Mucosa as a Potential Site for Diagnosis and Treatment of Allergic and Autoimmune Diseases.

Authors:  Cristina Gomez-Casado; Javier Sanchez-Solares; Elena Izquierdo; Araceli Díaz-Perales; Domingo Barber; María M Escribese
Journal:  Foods       Date:  2021-04-28

5.  Total Flavonoid Extract from Hawthorn (Crataegus pinnatifida) Improves Inflammatory Cytokines-Evoked Epithelial Barrier Deficit.

Authors:  Feng Liu; Xuesong Zhang; Yong Ji
Journal:  Med Sci Monit       Date:  2020-02-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.